HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

Samar Alanazi(University of Cincinnati Medical Center), Joan T. Garrett(University of Cincinnati Medical Center)

PLoS ONE

May 18, 2023

10.1371/journal.pone.0285251

Cited by 9

Related Papers

Current Advances in the Treatment of BRAF-Mutant Melanoma

|Cancers|2020|172

Activating HER3 mutations in breast cancer

|Oncotarget|2018|36

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

|Cancers|2021|33

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

|Anti-Cancer Drugs|2023|6